The advertisement promotes KEYTRUDA, a medication for treating advanced non-small cell lung cancer (NSCLC), and provides information on its use in combination with chemotherapy.
Creative Information
| CID: | f5021da0-39fe-414f-8828-c6eb7033f8f6 |
| CRID: | 2_206_449838 |
| Domain: | keytruda.com |
| Seat: | BSW |
| Size: | 728x90 |
| Bid: | $0.53 |
| Timestamp: | 10/31/2025, 2:14:35 AM |
| Declared IAB Categories: |
Analysis
5 succeeded(100% complete)
| Task | Status | Last Updated | Duration | Actions |
|---|---|---|---|---|
| ad_analysis | success | 11/19/2025, 1:34:23 AM | 7.00s | |
| adomain_analysis | success | 11/19/2025, 1:34:04 AM | 4.52s | |
| adomain_capture | success | 11/19/2025, 1:34:00 AM | 0.22s | |
| ad_render | success | 11/19/2025, 1:34:16 AM | 17.12s | |
| brand_mapping | success | 11/18/2025, 9:56:10 PM | 0.09s | |
Analysis Results
| Size: | 728x90 | ||||||||||||||||||||||
| Data Transferred: | 1766.29 KB | ||||||||||||||||||||||
| Render Time: | 8.41 Seconds | ||||||||||||||||||||||
| Creative Inferred IAB Categories: |
| ||||||||||||||||||||||
| Creative Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Domain Inferred IAB Categories: |
| ||||||||||||||||||||||
| Domain Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Total Ad Size: | 1785.42 KB | ||||||||||||||||||||||
| Requests Made: |
|
Advertiser Domain
Ad Preview
Raw Ad Markup
<ins class='dcmads' style='display:inline-block;width:728px;height:90px' data-dcm-placement='N464015.3848558MATTERKIND/B32794367.408772931' data-dcm-rendering-mode='script' data-dcm-https-only data-dcm-keywords='bc72ef52-c024-11f0-847a-42010ab2011c' data-dcm-click-tracker='https%3A%2F%2Frtb.adentifi.com%2FClicks%3FcrId%3D449838%3BsId%3D720132%3BlId%3D91614%3BcId%3D17823%3BadExchange%3DBidSwitch%3Baction%3Dclick%3BadId%3Dbc72ef52-c024-11f0-847a-42010ab2011c%3BadThdId%3Dad0b9fdda7b70ec8974961950fa3fd79%3BengineId%3D2883560618057597938%3BdIp%3DMTczLjI2LjE5My4yNDU%3BdIpv6%3D%3BadThdIdCode%3DWEB_MD5_V4%3BdealId%3D0%3BgeoId%3D203136%3BinventoryId%3D244697%3BrtdmIndicator%3D1%3Btimestamp%3D1762992446%3Blat%3DNDIuMDI%3Blong%3DLTkxLjY3%3Bdma%3DNjM3%3BstateCode%3D%3Bzip%3DNTI0MDI%3Bbsc%3D${CLICK_URL_ENC}%3Bredir%3D' data-dcm-resettable-device-id='' data-dcm-api-frameworks='[APIFRAMEWORKS]' data-dcm-omid-partner='[OMIDPARTNER]' data-dcm-gdpr-applies='gdpr=${GDPR}' data-dcm-gdpr-consent='gdpr_consent=${GDPR_CONSENT_755}' data-dcm-addtl-consent='addtl_consent=${ADDTL_CONSENT}' data-dcm-ltd='false' data-dcm-app-id=''> <script src='https://www.googletagservices.com/dcm/dcmads.js'></script></ins><img src='https://rtb.adentifi.com/Imps?impId=1;adId=bc72ef52-c024-11f0-847a-42010ab2011c;lId=91614;sId=720132;cId=17823;crId=449838;adThdId=ad0b9fdda7b70ec8974961950fa3fd79;adExchange=BidSwitch;engineId=2883560618057597938;dealId=0;geoId=203136;inventoryId=244697;rtdmIndicator=1;timestamp=1762992446;property=iambaker.net;dIp=MTczLjI2LjE5My4yNDU;dIpv6=;adThdIdCode=WEB_MD5_V4;thirdPartyIdType=1;npiKey=0;hhId=277976295;cuid=cuid_25f91910-a52c-11ee-b312-12a7adfcdbeb' style='display:none; width:0px; height:0px;' /><script src="https://tags.bkrtx.com/js/bk-coretag.js"></script><script>bk_addPageCtx("id","cuid_25f91910-a52c-11ee-b312-12a7adfcdbeb");bk_allow_multiple_calls = true;bk_use_multiple_iframes = true;bk_send_statid_payload = true;bk_use_image = true;bk_callback = true;bk_doJSTag(18840, 4);</script><span id="te-clearads-js-adtheorent01cont449838"><script type="text/javascript" src="//choices.truste.com/ca?pid=adtheorent01&aid=adtheorent01&cid=17823&c=adtheorent01cont449838&w=728&h=90&js=pmw0&plc=tr&uid=ad0b9fdda7b70ec8974961950fa3fd79"></script></span><img src="https://us-east-sync.bidswitch.net/sync?ssp=kargo&dsp_id=206&imp=1" alt=" " style="display:none"/>Creatives
